Cancer scientists say they have engineered a new type of super-strong antibody which could be used to boost the immune ...

Johnson & Johnson's (J&J) human neonatal Fc receptor (FcRn)-blocking monoclonal antibody Imaavy (nipocalimab-aahu) has ...

The US Food and Drug Administration has approved nipocalimab-aahu, a new FcRn- blocking monoclonal antibody, for the ...

Regeneron’s bispecific antibody linvoseltamab, now branded as Lynozyfic, has received conditional approval from the European ...

SHANGHAI, April 30, 2025 /PRNewswire/ -- Mabwell (688062), an innovation-driven biopharmaceutical company with entire industry chain, presented 6 study results of innovative drugs and platforms in ...

Tiziana Life Sciences Ltd (NASDAQ:TLSA) is a clinical-stage biotechnology company developing innovative immunotherapies for ...

By studying the effects of the nasal anti-CD3 in a ... Multiple Sclerosis: Cell-Catching Implant Helps Identify Successful Treatment in Mice Feb. 18, 2025 — A sponge-like implant in mice helped ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today shared new preclinical data for IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug ...

The European Commission (EC) has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody ...

After issues at a third-party manufacturer caused the FDA to reject Regeneron's multiple myeloma bispecific antibody ...

Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma Lynozyfic will provide a new option with convenient dosing and administration to patie ...

To overcome these limitations, Antengene developed ATG-201, a “2+1” CD19 x CD3 TCE, which was evaluated in a series of in ...